Detection of attenuated, noninfectious spirochetes in Borrelia burgdorferi-infected mice after antibiotic treatment

Journal of Infectious Diseases

Volumn 186, Issue 10, 2002, Pages 1430-1437

  Bockenstedt, Linda K ^a   Mao, Jialing ^a   Hodzic, Emir ^b   Barthold, Stephen W ^b   Fish, Durland ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; BACTERIAL DNA; CEFTRIAXONE; CORTISONE ACETATE; DOXYCYCLINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL GENE; BACTERIAL TRANSMISSION; BACTERIUM DETECTION; BORRELIA BURGDORFERI; CONTROLLED STUDY; CORRELATION ANALYSIS; DNA DETERMINATION; FEMALE; HISTOPATHOLOGY; IMMUNOFLUORESCENCE; IXODES SCAPULARIS; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PERSISTENT INFECTION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SPIROCHETE; TICK; TREATMENT OUTCOME; XENODIAGNOSIS;

ANIMALS; ANTI-BACTERIAL AGENTS; BORRELIA BURGDORFERI; DISEASE MODELS, ANIMAL; DNA, BACTERIAL; FEMALE; IMMUNOSUPPRESSION; LYME DISEASE; MICE; MICE, INBRED C3H; XENODIAGNOSIS;

EID: 0037111030     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/345284     Document Type: Article

References (48)

1. Bockenstedt LK, Malawista SE. Lyme disease. In: Rich RR. ed. Clinical Immunology. St. Louis: Mosby-Year Book. 1995:1234-49.
2. Steere AC. Lyme disease. N Engl J Med 2001;345:115-25.
3. Barthold SW, de Souza MS, Janotka JL, Smith AL, Persing DH. Chronic Lyme borreliosis in the laboratory mouse. Am J Pathol 1993;143:419-20.
4. Steere AC, Hutchinson GJ, Rahn DW, et al. Treatment of the early manifestations of Lyme disease. Ann Intern Med 1983;99:22-6.
5. Sigal LH. Persisting complaints attributed to chronic Lyme disease: Possible mechanisms and implications for management. Am J Med 1994;96:365-74.
6. Klempner MS, Hu LT, Evans J. et al. Two controlled trials of antibiotic treatment in patients with persistent symptoms and a history of Lyme disease. N Engl J Med 2001;345:85-92.
7. Johnson RC, Kodner C, Russell M. In vitro and in vivo susceptibility of the Lyme disease spirochete, Borrelia burgdorferi, to four antimicrobial agents. Antimicrob Agents Chemother 1987;31:164-7.
8. Johnson RC, Kodner C, Russell M. In vitro and in vivo susceptibility of Borrelia burgdorferi to azithromycin. J Antimicrob Chemother 1990;25(Suppl A): 33-8.
9. Johnson RC, Kodner CB, Jurkovich PJ. Collins JJ. Comparative in vitro and in vivo susceptibilities of the Lyme disease spirochete Borrelia burgdorferi to cefuroxime and other antimicrobial agents. Antimicrob Agents Chemother 1990;34:2133-6.
10. Mursic VP, Wilske B. Schierz G, Holmburger M, Suss E. In vitro and in vivo susceptibility of Borrelia burgdorferi. Eur J Clin Microbiol 1987;6:424-6.
11. Preac-Mursic V, Wilske B, Schierz G, Suss E. Gross B. Comparative antimicrobial activity of the macrolides against Borrelia burgdorferi. Eur J Clin Microbiol Infect Dis 1989;8:651-3.
12. Moody KD, Adams RL, Barthold SW. Effectiveness of antimicrobial treatment against Borrelia burgdorferi infection in mice. Antimicrob Agents Chemother 1994;38:1567-72.
13. Kazragis RJ, Dever LL, Jorgensen JH, Barbour AG. In vivo activities of ceftriaxone and vancomycin against Borrelia spp. in the mouse brain and other sites. Antimicrob Agents Chemother 1996;40:2632-6.
14. de Silva AM, Fikrig E. Borrelia burgdorferi genes selectively expressed in ticks and mammals. Parasitol Today 1997; 13:267-70.
15. de Silva AM, Fikrig E. Arthropod- and host-specific gene expression by Borrelia burgdorferi. J Clin Invest 1997;99:377-9.
16. Schwan TG, Piesman J, Golde WT, Dolan MC, Rosa PA. Induction of an outer surface protein on Borrelia burgdorferi during tick feeding. Proc Natl Acad Sci USA 1995;92:2909-13.
17. Zhang JR, Hardham JM, Barbour AG, Norris SJ. Antigenic variation in Lyme disease borreliae by promiscuous recombination of VMP-like sequence cassettes. Cell 1997;89:275-85.
18. Zhang JR. Norris SJ. Genetic variation of the Borrelia burgdorferi gene vlsE involves cassette-specific, segmental gene conversion. Infect Immun 1998;66:3698-704.
19. Zhang JR, Norris SJ. Kinetics and in vivo induction of genetic variation of vlsE in Borrelia burgdorferi. Infect Immun 1998;66:3689-97.
20. de Silva AM, Telford SR 3rd, Brunet LR, Barthold SW. Fikrig E. Borrelia burgdorferi OspA is an arthropod-specific transmission-blocking Lyme disease vaccine. J Exp Med 1996;183:271-5.
21. Ohnishi J, Piesman J, de Silva AM. Antigenic and genetic heterogeneity of Borrelia burgdorferi populations transmitted by ticks. Proc Natl Acad Sci USA 2001;98:670-5.
22. Straubinger RK, Straubinger AF, Summers BA, Jacobson RH. Status of Borrelia burgdorferi infection after antibiotic treatment and the effects of corticosteroids: An experimental study. J Infect Dis 2000; 181:1069-81.
23. Bockenstedt LK, Hodzic E, Feng S, et al. Borrelia burgdorferi strain-specific Osp C-mediated immunity in mice. Infect Immun 1997;65:4661-7.
24. Duong M, Ouellet N, Simard M, Bergeron Y, Olivier M, Bergeron MG. Kinetic study of host defense and inflammatory response to Aspergillus fumigatus in steroid-induced immunosuppressed mice. J Infect Dis 1998; 178:1472-82.
25. Scoles GA, Papero M, Beati L, Fish D. A relapsing fever group spirochete transmitted by Ixodes scapularis ticks. Vector Borne Zoonotic Dis 2001; 1:21-34.
26. Fraser CM, Casjens S, Huang WM, et al. Genomic sequence of a Lyme disease spirochaete, Borrelia burgdorferi. Nature 1997;390:580-6.
27. Feng S, Hodzic E, Barthold SW. Lyme arthritis resolution with antiserum to a 37-kilodalton Borrelia burgdorferi protein. Infect Immun 2000; 68:4169-73.
28. Purser JE, Norris SJ. Correlation between plasmid content and infectivity in Borrelia burgdorferi. Proc Natl Acad Sci USA 2000;97:13865-70.
29. Palmer N, Fraser C, Casjens S. Distribution of twelve linear extrachromosomal DNAs in natural isolates of Lyme disease spirochetes. J Bacteriol 2000;182:2476-80.
30. Malawista SE, Barthold SW, Persing DH. Fate of Borrelia burgdorferi DNA in tissues of infected mice after antibiotic treatment. J Infect Dis 1994; 170:1312-6.
31. Morrison TB, Ma Y, Weis JH, Weis JJ. Rapid and sensitive quantification of Borrelia burgdorferi-infected mouse tissues by continuous fluorescent monitoring of PCR. J Clin Microbiol 1999;37:987-92.
32. Hodzic E, Feng S, Fish D, Leutenegger CM, Freet KJ, Barthold SW. Infection of mice with the agent of human granulocytic ehrlichiosis after different routes of inoculation. J Infect Dis 2001;183:1781-6.
33. Kumar H, Belperron A, Barthold SW, Bockenstedt LK. Cutting edge: CDI deficiency impairs early murine host defense against the spirochete. Borrelia burgdorferi. J Immunol 2000; 165:4797-801.
34. Barthold SW, Beck DS, Hansen GM, Terwilliger GA, Moody KD. Lyme borreliosis in selected strains and ages of laboratory mice. J Infect Dis 1990;162:133-8.
35. Domingo S, Gastearena I, Vitas AI. et al. Comparative activity of azithromycin and doxycycline against Brucella spp. infection in mice. J Antimicrob Chemother 1995;36:647-56.
36. Barthold SW, Fikrig E, Bockenstedt LK, Persing DH. Circumvention of outer surface protein A immunity by host-adapted Borrelia burgdorferi. Infect Immun 1995; 63:2255-61.
37. Anderson JF, Epizootiology of Lyme borreliosis. Scand J Infect Dis Suppl 1991;77:23-34.
38. Fish D. Population ecology of Ixodes dammini. In: Ginsberg H, ed. Ecology and environmental management of Lyme disease. New Brunswick, NJ: Rutgers University Press, 1993:25-42.
39. Eagle H, Musselman AD. The rate of bactericidal action of penicillin in vitro as a function of its concentration and its paradoxically reduced activity at high concentrations against certain organisms. J Exp Med 1948; 88:99-131.
40. Georgilis K, Peacocke M, Klempner MS. Fibroblasts protect the Lyme disease spirochete, Borrelia burgdorferi, from ceftriaxone in vitro. J Infect Dis 1992; 166:440-4.
41. Brouqui P, Badiaga S, Raoult D. Eucaryotic cells protect Borrelia burgdorferi from the action of penicillin and ceftriaxone but not from the action of doxycycline and erythromycin. Antimicrob Agents Chemother 1996;40:1552-14.
42. Schwan TG, Burgdorfer W. Garon CF. Changes in infectivity and plasmid profile of the Lyme disease spirochete, Borrelia burgdorferi, as a result of in vitro cultivation. Infect Immun 1988; 56:1831-6.
43. Norris SJ, Howell JK, Barbour AG. Low-passage-associated proteins of Borrelia burgdorferi B31: Characterization and molecular cloning of OspD, a surface-exposed, plasmid-encoded lipoprotein. Infect Immun 1992;60:4662-72.
44. Anguita J, Samanta S, Revilla B, et al. Borrelia burgdorferi gene expression in vivo and spirochete pathogenicity. Infect Immun 2000;68:1222-30.
45. Inman RD, Whittum-Hudson JA, Schumacher HR, Hudson AP. Chlamydia and associated arthritis. Curr Opin Rheumatol 2000; 12:254-2.
46. Sultan L, Nyka W, Mills C, O'Grady F, Wells W, Riley RL. Tuberculosis disseminators: A study of the aerial infectivity of tuberculous patients. Am Rev Respir Dis 1960;82:358-69.
47. Riley RL, Mills CC, O'Grady F, Sultan LU, Wittstadt F, Shivpuri DN. Infectiousness of air from a tuberculosis ward. Am Rev Respir Dis 1962;85:511-25.
48. Vidal R, Martin-Casabona N, Juan A, Falguera T, Miravitlles M. Incidence and significance of acid-fast bacilli in sputum smears at the end of antituberculous treatment. Chest 1996; 109:1562-5.